Pharma markets increasingly ignore Trump pricing rhetoric

10 July 2018

In a sign that pharma investors are becoming increasingly inured to outpourings from US President Donald Trump around drug pricing, markets were unrattled on Monday by a furious tweet singling out New York’s Pfizer (NYSE: PFE).

Referring to the the pharma major’s recent decision to increase the price of 100 products from the start of July, he said: "Pfizer & others should be ashamed that they have raised drug prices for no reason.”

The price hikes, revealed by the Financial Times, are mostly in excess of 9%, well above the 2% US inflation rate. Mr Trump tweeted, “They are merely taking advantage of the poor & others unable to defend themselves.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK